Markers of liver function as potential prognostic indicators of SARS-CoV-2 infection: A retrospective analysis during the first and second waves of COVID-19 pandemic.
COVID-19
ICU
SARS-CoV-2 infection
in-hospital mortality
liver disease
Journal
Le infezioni in medicina
ISSN: 2532-8689
Titre abrégé: Infez Med
Pays: Italy
ID NLM: 9613961
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
02
2023
accepted:
02
05
2023
medline:
7
6
2023
pubmed:
7
6
2023
entrez:
7
6
2023
Statut:
epublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is known to cause a predominant respiratory disease, although extrapulmonary manifestations can also occur. One of the targets of Coronavirus disease 2019 (COVID-19) is the hepatobiliary system. The present study aims to describe the correlation between the increase of liver damage markers ( All patients with confirmed SARS-CoV-2 infection admitted to the Infectious Diseases Unit of the St. Anna University-Hospital of Ferrara from March 2020 to October 2021 were retrospectively included in this single-centre study. ALT, AST and TB levels were tested in all patients and IHM or ICU transfer were considered as main outcomes. Co-morbidities were assessed using Charlson Comorbidity Index. A total of 106 patients were retrieved. No hepatic marker was able to predict IHM, whereas all of them negatively predicted ICU transfer (ALT: OR 1.005, 95%CI 1.001-1.009, p= 0.011; AST: OR 1.018, 95%CI 1.006-1.030, p= 0.003; TB: OR 1.329, 95%CI 1.025-1.724, p= 0.032). Age was the only parameter significantly related to mortality. The present study, by correlating liver damage markers with COVID-19 outcome, showed that an increase of ALT, AST and TB predicted patients' severity, although not mortality.
Sections du résumé
Background
UNASSIGNED
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is known to cause a predominant respiratory disease, although extrapulmonary manifestations can also occur. One of the targets of Coronavirus disease 2019 (COVID-19) is the hepatobiliary system. The present study aims to describe the correlation between the increase of liver damage markers (
Methods
UNASSIGNED
All patients with confirmed SARS-CoV-2 infection admitted to the Infectious Diseases Unit of the St. Anna University-Hospital of Ferrara from March 2020 to October 2021 were retrospectively included in this single-centre study. ALT, AST and TB levels were tested in all patients and IHM or ICU transfer were considered as main outcomes. Co-morbidities were assessed using Charlson Comorbidity Index.
Results
UNASSIGNED
A total of 106 patients were retrieved. No hepatic marker was able to predict IHM, whereas all of them negatively predicted ICU transfer (ALT: OR 1.005, 95%CI 1.001-1.009, p= 0.011; AST: OR 1.018, 95%CI 1.006-1.030, p= 0.003; TB: OR 1.329, 95%CI 1.025-1.724, p= 0.032). Age was the only parameter significantly related to mortality.
Conclusions
UNASSIGNED
The present study, by correlating liver damage markers with COVID-19 outcome, showed that an increase of ALT, AST and TB predicted patients' severity, although not mortality.
Identifiants
pubmed: 37283636
doi: 10.53854/liim-3102-9
pii: 1124-9390_31_1_2023_209-214
pmc: PMC10241392
doi:
Types de publication
Journal Article
Langues
eng
Pagination
209-214Déclaration de conflit d'intérêts
Conflicts of interest The authors declare no conflict of interest.
Références
Eur J Clin Invest. 2003 Aug;33(8):720-5
pubmed: 12864783
Eur J Gastroenterol Hepatol. 2021 Mar 1;33(3):309-311
pubmed: 32558697
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
Infez Med. 2020 Jun 1;28(suppl 1):96-103
pubmed: 32532945
Liver Int. 2021 Jan;41(1):20-32
pubmed: 33190346
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2004 May;16(5):267-70
pubmed: 15132787
Clin Gastroenterol Hepatol. 2020 Jun;18(7):1561-1566
pubmed: 32283325
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
Eur Rev Med Pharmacol Sci. 2020 Oct;24(19):10239-10246
pubmed: 33090435
Microorganisms. 2022 Jun 10;10(6):
pubmed: 35744711
Infez Med. 2021 Dec 10;29(4):550-556
pubmed: 35146363
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Pathol. 2022 Nov;258(3):211-212
pubmed: 36002997
Eur J Med Res. 2020 Aug 3;25(1):30
pubmed: 32746929
J Med Virol. 2020 Sep;92(9):1491-1494
pubmed: 32369204
Hepatology. 2020 Aug;72(2):389-398
pubmed: 32359177
Microbiol Immunol. 2015 Jul;59(7):375-80
pubmed: 26011190
Microorganisms. 2020 Aug 12;8(8):
pubmed: 32806657
J Hepatol. 2020 Sep;73(3):566-574
pubmed: 32298767
Microorganisms. 2022 Aug 12;10(8):
pubmed: 36014055
Liver Int. 2020 Jun;40(6):1278-1281
pubmed: 32251539
Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028
pubmed: 32286245
J Clin Transl Hepatol. 2020 Mar 28;8(1):13-17
pubmed: 32274341
Microorganisms. 2022 Apr 12;10(4):
pubmed: 35456856
Infez Med. 2022 Mar 1;30(1):80-85
pubmed: 35350260
Discov Med. 2020 Sep-Oct;30(160):107-112
pubmed: 33382966
Crit Rev Clin Lab Sci. 2020 Sep;57(6):389-399
pubmed: 32503382